HIPO 最新10-Q变化
将 HIPO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-07-30 与上一份 10-Q · 2026-04-30
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +40 | −33 | ~32 | 98 |
| 市场风险(第3项) | 文字有新增/删除 | +40 | −33 | ~32 | 97 |
| 控制与程序 | 文字有新增/删除 | +40 | −33 | ~32 | 97 |
| 法律诉讼 | 文字有新增/删除 | +40 | −33 | ~32 | 97 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | +40 | −33 | ~32 | 97 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
相对上期删除的文字 · 来源:10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
相对上期删除的文字 · 来源:10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
相对上期删除的文字 · 来源:10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
相对上期删除的文字 · 来源:10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
相对上期删除的文字 · 来源:10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议